CA Patent

CA3268119A1 — Sterilized heterocyclidene-acetamide-derivative-containing suspension

Assigned to Senju Pharmaceutical Co Ltd · Expires 2025-10-31 · 1y expired

What this patent protects

The present disclosure provides a suspension ophthalmic solution having exceptional re-dispersibility. More specifically, the present disclosure provides an aqueous suspension containing heat-treated (E)-2-(7-trifluoromethylchroman-4-yldene)-N-(7-hydroxy-5,6,7,8-tetrahydronaphtha…

USPTO Abstract

The present disclosure provides a suspension ophthalmic solution having exceptional re-dispersibility. More specifically, the present disclosure provides an aqueous suspension containing heat-treated (E)-2-(7-trifluoromethylchroman-4-yldene)-N-(7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)acetamide or a pharmacologically acceptable salt or solvate thereof. In particular, the present disclosure relates to technology for improving the re-dispersibility of a suspension that contains a heterocyclidene acetamide derivative or to formulation technology based thereupon.

Drugs covered by this patent

Patent Metadata

Patent number
CA3268119A1
Jurisdiction
CA
Classification
—
Expires
2025-10-31
Drug substance claim
No
Drug product claim
No
Assignee
Senju Pharmaceutical Co Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.